• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma.在阿维鲁单抗维持治疗转移性尿路上皮癌期间顺铂诱导的治疗相关骨髓增生异常综合征
Int Cancer Conf J. 2025 Jan 24;14(2):73-78. doi: 10.1007/s13691-024-00735-w. eCollection 2025 Apr.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.阿维鲁单抗用于过敏反应和转移性尿路上皮癌的管理与脱敏：一例报告
J Oncol Pharm Pract. 2025 Jul;31(5):839-841. doi: 10.1177/10781552241313057. Epub 2025 Feb 13.
4
A systematic overview of radiation therapy effects in urinary bladder cancer.膀胱癌放射治疗效果的系统综述。
Acta Oncol. 2003;42(5-6):567-81. doi: 10.1080/02841860310014408.
5
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.阿维鲁单抗用于肌层浸润性膀胱癌患者的新辅助治疗（AURA Oncodistinct-004）：一项2期多中心临床试验。
J Immunother Cancer. 2025 May 24;13(5):e012045. doi: 10.1136/jitc-2025-012045.
6
A systematic overview of chemotherapy effects in non-small cell lung cancer.非小细胞肺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):327-39. doi: 10.1080/02841860151116402.
7
A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.关于阿维鲁单抗一线维持治疗及局部晚期或转移性尿路上皮癌治疗顺序的真实世界证据播客。
Target Oncol. 2025 Jul 1. doi: 10.1007/s11523-025-01162-4.
8
A systematic overview of chemotherapy effects in urothelial bladder cancer.尿路上皮膀胱癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):371-90. doi: 10.1080/02841860151116466.
9
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.吉西他滨用于不可切除的局部晚期或转移性膀胱癌。
Cochrane Database Syst Rev. 2011 Apr 13(4):CD008976. doi: 10.1002/14651858.CD008976.pub2.
10
WITHDRAWN: Neoadjuvant cisplatin for advanced bladder cancer.撤回：新辅助顺铂用于晚期膀胱癌。
Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD001426. doi: 10.1002/14651858.CD001426.pub2.

本文引用的文献

1
Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.在接受恩杂鲁胺治疗转移性尿路上皮癌后发生的骨髓增生异常综合征。
IJU Case Rep. 2024 Jun 10;7(4):316-319. doi: 10.1002/iju5.12734. eCollection 2024 Jul.
2
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.avelumab 一线维持治疗晚期尿路上皮癌：≥2 年随访的 JAVELIN Bladder 100 试验结果。
J Clin Oncol. 2023 Jul 1;41(19):3486-3492. doi: 10.1200/JCO.22.01792. Epub 2023 Apr 18.
3
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.基于原发疾病和治疗的治疗相关性 MDS 解析：一项全国性视角。
Leukemia. 2023 May;37(5):1103-1112. doi: 10.1038/s41375-023-01864-6. Epub 2023 Mar 17.
4
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.一线化疗后切换维持avelumab 免疫治疗用于晚期、不可切除或转移性尿路上皮癌患者：来自多中心研究的首个日本真实世界证据。
Jpn J Clin Oncol. 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186.
5
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.恩福妥单抗 Vedotin 治疗既往治疗的晚期尿路上皮癌。
N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.
6
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.治疗相关性骨髓增生异常综合征需要进行特定的诊断亚分类和风险分层——一种用于 t-MDS 患者分类的方法。
Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29.
7
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?免疫检查点抑制剂相关的血液学免疫不良反应，如何管理？
Eur J Cancer. 2019 Nov;122:72-90. doi: 10.1016/j.ejca.2019.07.014. Epub 2019 Oct 18.
8
Long-term toxicity of cisplatin in germ-cell tumor survivors.顺铂对生殖细胞肿瘤幸存者的长期毒性
Ann Oncol. 2017 Nov 1;28(11):2670-2679. doi: 10.1093/annonc/mdx360.
9
Therapy-related myeloid neoplasms: when genetics and environment collide.治疗相关的髓系肿瘤：遗传学与环境的碰撞
Nat Rev Cancer. 2017 Aug 24;17(9):513-527. doi: 10.1038/nrc.2017.60.
10
Therapy-related myelodysplastic syndromes, or are they?与治疗相关的骨髓增生异常综合征，真的是这样吗？
Blood Rev. 2017 May;31(3):119-128. doi: 10.1016/j.blre.2016.11.002. Epub 2016 Nov 24.

在阿维鲁单抗维持治疗转移性尿路上皮癌期间顺铂诱导的治疗相关骨髓增生异常综合征

Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma.

作者信息

Sugino Yusuke, Nishikawa Taketomo, Inaba Sota, Owa Shunsuke, Kato Momoko, Higashi Shinichiro, Sasaki Takeshi, Masui Satoru, Nishikawa Kouhei, Nakamura Akihide, Usui Miki, Inoue Takahiro

机构信息

Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie Japan.

Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Mie Japan.

出版信息

Int Cancer Conf J. 2025 Jan 24;14(2):73-78. doi: 10.1007/s13691-024-00735-w. eCollection 2025 Apr.

DOI:10.1007/s13691-024-00735-w
PMID:40160873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11950612/
Abstract

A 64 year-old man underwent a radical cystectomy for muscle-invasive bladder cancer. Five years later, lung and mediastinal lymph node metastases were detected. After 15 courses of gemcitabine and cisplatin for metastatic urothelial carcinoma, the patient was switched to avelumab maintenance therapy. During this period, the patient developed a therapy-related myelodysplastic syndrome, leading to difficulty in continuing treatment. Therapy-related myelodysplastic syndrome is a dose-dependent complication that can develop several years after chemotherapy or radiotherapy. Therefore, excessive cisplatin administration should be avoided.

摘要

一名64岁男性因肌层浸润性膀胱癌接受了根治性膀胱切除术。五年后，检测到肺部和纵隔淋巴结转移。在接受了15个疗程的吉西他滨和顺铂治疗转移性尿路上皮癌后，患者改为接受阿维鲁单抗维持治疗。在此期间，患者出现了与治疗相关的骨髓增生异常综合征，导致难以继续治疗。与治疗相关的骨髓增生异常综合征是一种剂量依赖性并发症，可在化疗或放疗后数年发生。因此，应避免过量使用顺铂。